![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SNF8 |
Gene summary for SNF8 |
![]() |
Gene information | Species | Human | Gene symbol | SNF8 | Gene ID | 11267 |
Gene name | SNF8 subunit of ESCRT-II | |
Gene Alias | Dot3 | |
Cytomap | 17q21.32 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96H20 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11267 | SNF8 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.00e-04 | 2.58e-01 | -0.1808 |
11267 | SNF8 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.39e-03 | 2.58e-01 | -0.0811 |
11267 | SNF8 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.48e-14 | 3.75e-01 | -0.1954 |
11267 | SNF8 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.95e-06 | 3.58e-01 | -0.1207 |
11267 | SNF8 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.08e-15 | 5.25e-01 | -0.1464 |
11267 | SNF8 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.71e-06 | 2.50e-01 | -0.1001 |
11267 | SNF8 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.27e-08 | 3.50e-01 | -0.059 |
11267 | SNF8 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.15e-10 | 5.87e-01 | -0.1706 |
11267 | SNF8 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.55e-02 | 2.98e-01 | -0.0842 |
11267 | SNF8 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.22e-04 | 2.32e-01 | 0.096 |
11267 | SNF8 | HTA11_10623_2000001011 | Human | Colorectum | AD | 5.47e-08 | 4.92e-01 | -0.0177 |
11267 | SNF8 | HTA11_6801_2000001011 | Human | Colorectum | SER | 9.50e-04 | 6.37e-01 | 0.0171 |
11267 | SNF8 | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.20e-08 | 3.07e-01 | 0.0674 |
11267 | SNF8 | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.86e-06 | 3.45e-01 | 0.0588 |
11267 | SNF8 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.00e-07 | 3.70e-01 | 0.3859 |
11267 | SNF8 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.37e-12 | 4.23e-01 | 0.3005 |
11267 | SNF8 | LZE4T | Human | Esophagus | ESCC | 2.38e-04 | 1.29e-01 | 0.0811 |
11267 | SNF8 | LZE5T | Human | Esophagus | ESCC | 8.22e-07 | 4.61e-01 | 0.0514 |
11267 | SNF8 | LZE7T | Human | Esophagus | ESCC | 9.94e-11 | 5.92e-01 | 0.0667 |
11267 | SNF8 | LZE8T | Human | Esophagus | ESCC | 3.85e-10 | 1.79e-01 | 0.067 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00325096 | Oral cavity | OSCC | endosome transport via multivesicular body sorting pathway | 27/7305 | 31/18723 | 4.29e-08 | 8.03e-07 | 27 |
GO:00397026 | Oral cavity | OSCC | viral budding via host ESCRT complex | 20/7305 | 21/18723 | 8.69e-08 | 1.52e-06 | 20 |
GO:00190686 | Oral cavity | OSCC | virion assembly | 29/7305 | 35/18723 | 1.30e-07 | 2.20e-06 | 29 |
GO:00453244 | Oral cavity | OSCC | late endosome to vacuole transport | 22/7305 | 25/18723 | 5.68e-07 | 8.19e-06 | 22 |
GO:00467555 | Oral cavity | OSCC | viral budding | 22/7305 | 26/18723 | 2.32e-06 | 2.93e-05 | 22 |
GO:00325112 | Oral cavity | OSCC | late endosome to vacuole transport via multivesicular body sorting pathway | 16/7305 | 17/18723 | 3.07e-06 | 3.72e-05 | 16 |
GO:00988769 | Oral cavity | OSCC | vesicle-mediated transport to the plasma membrane | 79/7305 | 136/18723 | 4.93e-06 | 5.58e-05 | 79 |
GO:00726658 | Oral cavity | OSCC | protein localization to vacuole | 44/7305 | 67/18723 | 8.92e-06 | 9.44e-05 | 44 |
GO:00989277 | Oral cavity | OSCC | vesicle-mediated transport between endosomal compartments | 31/7305 | 43/18723 | 1.10e-05 | 1.14e-04 | 31 |
GO:00450225 | Oral cavity | OSCC | early endosome to late endosome transport | 28/7305 | 40/18723 | 7.00e-05 | 5.60e-04 | 28 |
GO:00726667 | Oral cavity | OSCC | establishment of protein localization to vacuole | 32/7305 | 49/18723 | 1.73e-04 | 1.19e-03 | 32 |
GO:19035436 | Oral cavity | OSCC | positive regulation of exosomal secretion | 13/7305 | 15/18723 | 2.07e-04 | 1.36e-03 | 13 |
GO:19901829 | Oral cavity | OSCC | exosomal secretion | 16/7305 | 20/18723 | 2.24e-04 | 1.46e-03 | 16 |
GO:00977349 | Oral cavity | OSCC | extracellular exosome biogenesis | 16/7305 | 21/18723 | 5.99e-04 | 3.39e-03 | 16 |
GO:00431622 | Oral cavity | OSCC | ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 17/7305 | 23/18723 | 7.28e-04 | 3.98e-03 | 17 |
GO:01401127 | Oral cavity | OSCC | extracellular vesicle biogenesis | 17/7305 | 23/18723 | 7.28e-04 | 3.98e-03 | 17 |
GO:19035418 | Oral cavity | OSCC | regulation of exosomal secretion | 13/7305 | 17/18723 | 1.92e-03 | 8.94e-03 | 13 |
GO:0016032110 | Oral cavity | LP | viral process | 211/4623 | 415/18723 | 4.06e-31 | 3.18e-28 | 211 |
GO:007259419 | Oral cavity | LP | establishment of protein localization to organelle | 205/4623 | 422/18723 | 6.76e-27 | 3.85e-24 | 205 |
GO:0019058110 | Oral cavity | LP | viral life cycle | 161/4623 | 317/18723 | 5.99e-24 | 2.21e-21 | 161 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa0414428 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
hsa0414436 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
hsa0414425 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
hsa04144111 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
hsa0414426 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
hsa0414435 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SNF8 | SNV | Missense_Mutation | c.52N>C | p.Glu18Gln | p.E18Q | Q96H20 | protein_coding | tolerated(1) | benign(0.084) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SNF8 | SNV | Missense_Mutation | c.171N>C | p.Glu57Asp | p.E57D | Q96H20 | protein_coding | tolerated(0.87) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SNF8 | SNV | Missense_Mutation | c.39N>T | p.Lys13Asn | p.K13N | Q96H20 | protein_coding | tolerated(0.3) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SNF8 | SNV | Missense_Mutation | c.594N>G | p.Ile198Met | p.I198M | Q96H20 | protein_coding | deleterious(0) | possibly_damaging(0.572) | TCGA-C8-A278-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
SNF8 | deletion | Frame_Shift_Del | novel | c.691delN | p.Glu231ArgfsTer95 | p.E231Rfs*95 | Q96H20 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
SNF8 | deletion | Frame_Shift_Del | novel | c.578delT | p.Val193GlyfsTer25 | p.V193Gfs*25 | Q96H20 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
SNF8 | SNV | Missense_Mutation | novel | c.494N>A | p.Gly165Asp | p.G165D | Q96H20 | protein_coding | tolerated(0.08) | possibly_damaging(0.658) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SNF8 | SNV | Missense_Mutation | c.295N>A | p.Glu99Lys | p.E99K | Q96H20 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SNF8 | SNV | Missense_Mutation | c.350G>C | p.Gly117Ala | p.G117A | Q96H20 | protein_coding | deleterious(0) | benign(0.158) | TCGA-DM-A1D4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SNF8 | SNV | Missense_Mutation | c.170N>T | p.Glu57Val | p.E57V | Q96H20 | protein_coding | deleterious(0) | possibly_damaging(0.514) | TCGA-F5-6702-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | oxaliplatin | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |